Thermo Fisher Scientific Inc.
TMO
Below: live stock price for Thermo Fisher Scientific Inc. (TMO), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Thermo Fisher Scientific Inc. (TMO) is a Healthcare company based in United States. Operating in Diagnostics & Research, it employs about 125,000 people. Over the past year TMO traded between 435.27 and 711.85 USD. Trailing P/E sits near 37.41 on a market cap of about 258.25B USD. It currently yields 0.27% in dividends.
- Prev close
- $709.18
- Volume (24h)
- $1.46B
- Market cap
- $258.25B
- Currency
- USD
Score
50/ 100 · Mixed
- Value30
- Quality53
- Momentum49
- Growth41
- Risk83
- Dividend52
- Liquidity43
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 704.7178 +1.11%
- +20 bars
- 715.5071 +2.66%
- +60 bars
- 719.7253 +3.26%
- +120 bars
- 719.8804 +3.28%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.61% per bar.
Interpretation
Composite signals look mixed. Strength: risk profile with weakness: valuation. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value30/100
Value looks weak — driven by P/E (37.41).
P/E:37.41P/B:4.71PEG:2.03 - Quality53/100
Quality looks mixed — driven by Gross margin (41.17%).
ROE:13.38%ROA:5.23%Profit margin:14.94%Gross margin:41.17% - Momentum49/100
Momentum looks mixed — driven by 52w change (23.39%).
52w change:23.39% - Growth41/100
Growth looks weak — driven by Revenue growth (9.10%).
Revenue growth:9.10%Earnings growth:8.70% - Risk83/100
Risk looks strong — driven by Debt / equity (75.36).
Beta:0.88Debt / equity:75.36Short interest:1.32% - Dividend52/100
Dividend looks mixed — driven by Payout ratio (9.70%).
Dividend yield:0.27%Payout ratio:9.70% - Liquidity43/100
Liquidity looks weak — driven by Current ratio (1.81).
Current ratio:1.81Quick ratio:1.11
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 29.3%
- Max drawdown
- -31.5%
- Below period high
- -2.1%
- Best day
- +8.71%
- Worst day
- -9.20%
- Up days
- 51%
- Current streak
- 1 down
- Typical day swing
- 2.6%
- Volume vs average
- +42%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 711.85 high → 574.77 low · 60 bars
- ResistanceFib +161.8% extensionnot reached933.6453 USD+33.95% from current
- ResistanceFib +100% extensionnot reached848.9299 USD+21.80% from current
- ResistanceFib +61.8% extensionnot reached796.5654 USD+14.28% from current
- ResistanceFib +27.2% extensionnot reached749.1357 USD+7.48% from current
- Current697 USD
- SupportFib 23.6% retracementNearesttested 13×679.4991 USD-2.51% from current
- SupportFib 38.2% retracementtested 14×659.4854 USD-5.38% from current
- SupportFib 50% midpointtested 3×643.31 USD-7.70% from current
- SupportFib 61.8% retracementtested 8×627.1346 USD-10.02% from current
- SupportFib 78.6% retracementtested 10×604.1051 USD-13.33% from current
- SupportFib −27.2% extensionnot reached537.4843 USD-22.89% from current
- SupportFib −61.8% extensionnot reached490.0546 USD-29.69% from current
- SupportFib −100% extensionnot reached437.6901 USD-37.20% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $711.85
- 52w low
- $435.27
- 52w change
- 23.39%
- Day high
- $711.79
- Day low
- $691.74
- P/E (TTM)
- 37.41
- Forward P/E
- 25.1
- PEG
- 2.03
- Price / Book
- 4.71
- Beta (5Y)
- 0.88
- Enterprise value
- 293.33B
- EV / Revenue
- 6.2
- EV / EBITDA
- 24.05
- EPS (TTM)
- $18.63
- Forward EPS
- $27.77
- Dividend yield
- 0.27%
- Dividend rate
- $1.88
- Payout ratio
- 9.70%
- Revenue (TTM)
- 47.35B
- EBITDA
- 12.2B
- Free cash flow
- 6.45B
- Total cash
- 6.06B
- Total debt
- 41.37B
- Debt / Equity
- 75.36
- Current ratio
- 1.81
- Quick ratio
- 1.11
- Profit margin
- 14.94%
- Gross margin
- 41.17%
- Return on assets
- 5.23%
- Return on equity
- 13.38%
- Shares outstanding
- 370.52M
- Float
- 369.08M
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.88
- less volatile
- 52-week change
- 23.39%
- Short % of float
- 1.32%
- Short ratio (days)
- 1.98
- Debt / Equity
- 75.36
- very high leverage
- Current ratio
- 1.81
- Quick ratio
- 1.11
- ROE
- 13.38%
- ROA
- 5.23%
- PEG ratio
- 2.03
- EV / Revenue
- 6.2
- EV / EBITDA
- 24.05
- Revenue growth
- 9.10%
- Earnings growth
- 8.70%
- EBITDA
- 12.2B
- Free cash flow
- 6.45B
- Total cash
- 6.06B
- Total debt
- 41.37B
- Insider holdings
- 0.13%
- Institutional
- 93.46%
Recent rating changes
- 2026-10-30Argus ResearchBuy → Buymain
- 2026-10-23CitigroupBuy → Buymain
- 2026-10-22BarclaysOverweight → Overweightmain
- 2026-10-22RBC CapitalSector Perform → Sector Performmain
- 2026-10-22TD CowenBuy → Buymain
- 2026-10-22StifelBuy → Buymain
- 2026-10-22BairdOutperform → Outperformmain
- 2026-10-13Morgan StanleyOverweight → Overweightmain
Financial documents
- Corporate Changes & Voting Matters8-K2026-10-30
- Corporate Changes & Voting Matters8-K2026-10-21
- Periodic Financial Reports10-Q2026-07-31
- Corporate Changes & Voting Matters8-K2026-07-23
- Annual report of employee stock purchase11-K2026-06-23
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-28
- Corporate Changes & Voting Matters8-K2026-05-26
- Proxy StatementsDEFA14A2026-05-11
- Periodic Financial Reports10-Q2026-05-01
- Corporate Changes & Voting Matters8-K2026-04-23
- Proxy StatementsDEF 14A2026-04-07
- Corporate Changes & Voting Matters8-K2026-03-24
Recent news
- How Investors Are Reacting To Thermo Fisher Scientific Stock After Strong Q3 EarningsSimply Wall St.15 hr. ago
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENGlobeNewswireyesterday
- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AIGlobeNewswireyesterday
- Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and RocheGlobeNewswireyesterday
- Clinical Genomics Sequencing, Biobank, and Database Services Global Market to 2035 | Capitalize on AI and Precision Medicine: Illumina, Thermo Fisher, BGI Genomics, Tempus AIGlobeNewswireyesterday
- Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex DiagnosticsGlobeNewswireyesterday
- Global Fetal Aneuploidy Confirmation Testing Market Report 2026 | Capitalize on 10.6% CAGR to $2.36 Billion by 2030 with Thermo Fisher, Labcorp, Quest Diagnostics and IlluminaGlobeNewswireyesterday
- Global Gene Panel Reconciliation Services Market Report 2026 | Capitalize on AI-Driven Genomics as Roche, Thermo Fisher, Illumina and QIAGEN Accelerate a $2.38B Market by 2030GlobeNewswireyesterday
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.